Imatinib Completed Phase 2 Trials for Philadelphia Positive Chronic Myeloid Leukemia in Myeloid Blast Crisis Treatment

IndicationsStatusPurposePhase
CompletedTreatment2
clinicaltrials.gov IdentifierTitleDrugs
NCT00171158An Extension Study of the Safety and Anti-leukemic Effects of Imatinib Mesylate in Patients (Male or Female ≥18 Years) With Ph + CML in Blast Crisis